Work

Mechanisms of Resistance in Therapy With Angiogenesis Blockers in Colorectal Cancer

Year: 2022

Type: article

Abstract: One of the fundamental events that determine carcinogenesis and its progression is angiogenesis mediated by the activation of the vascular endothelial growth factor (VEGF). The angiogenic cascade provides a comfortable micro-environment for the tumor, the creation of a metastatic niche and subsequent metastatic dissemination of neoplastic cells. The development of a recombinant hyperchimeric monoclonal antibody that selectively binds and inhibits the biological activity of VEGF - Bevacizumab, has led to a change in the therapeutic strategy for patients with cancer and, in particular, for patients with metastatic colorectal cancer (CRC), because it demonstrated an increase in their survival rate.

Source: Cardiometry

DOI: 10.18137/cardiometry.2022.24.conf.37

Authors: Golubinskaya, Е.P., Seferov, B.D., Kalfa, М.А., Fomochkina, I.I., Kubyshkin, V.А.

Language: English

Topic: Angiogenesis and VEGF in Cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $200

OpenAlex ID: W4312200039

FWCI:

Cites: 54

Cited by:

Related to: 10